Anti-PD-1 Antibody, Non-Fucosylated (CAT#: BioBet-409ZP) Datasheet

PDCD1

Programmed Cell Death 1

This gene encodes a cell surface membrane protein of the immunoglobulin superfamily. This protein is expressed in pro-B-cells and is thought to play a role in their differentiation. In mice, expression of this gene is induced in the thymus when anti-CD3 antibodies are injected and large numbers of thymocytes undergo apoptosis. Mice deficient for this gene bred on a BALB/c background developed dilated cardiomyopathy and died from congestive heart failure. These studies suggest that this gene product may also be important in T cell function and contribute to the prevention of autoimmune diseases. [provided by RefSeq, Jul 2008]

Pidilizumab;1310680-64-8;CT-011;hBat-1;CT-011;PDCD1;programmed cell death 1;programmed cell death protein 1;CD279;PD1;protein PD-1;PD-1;SLEB2;hPD-1;hPD-l;

Plasma membrane

Diseases associated with PDCD1 include Systemic Lupus Erythematosus 2 and Multiple Sclerosis.

Its related pathways are T cell receptor signaling pathway and Innate Immune System.

Antigens activate the inhibitory receptors of T cells and play a key role in inducing and maintaining autoimmune tolerance. When combined with ligands CD274/PDCD1L1 and CD273/PDCD1LG2, it delivers inhibitory signals. After the participation of t cell receptor (TCR), PDCD1 binds to CD3-TCR at the immune synapse and directly inhibits T cell activation (through similarity). Inhibition of t cell activation by recruiting PTPN11/SHP-2: After ligand binding, PDCD1 is phosphorylated in the ITSM motif, which leads to the recruitment of protein tyrosine phosphatase PTPN11/SHP-2, which mediates the deactivation of key TCR proximal signaling molecules. Phosphorylation, such as ZAP70, PRKCQ/PKCtheta and CD247/CD3zeta. Tumors use pdcd1-mediated inhibition to weaken anti-tumor immunity and escape the destruction of the immune system, thereby promoting tumor survival. Interaction with CD274/PDCD1L1 can inhibit the effector function of cytotoxic T lymphocytes (CTLs). The blockade of pdcd1 mediated pathway leads to the reversal of the phenotype of exhausted T cells and the normalization of anti-tumor response, which provides a theoretical basis for cancer immunotherapy.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG1, κ

BioBet-409ZP

Humanized

Human

ADCC-enhanced Pidilizumab is a non-fucosylated anti-PD-1 therapeutic biobetter antibody.

Hodgkin lymphoma

Hodgkin lymphoma